Literature DB >> 22499458

Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial).

I Carrié1, G Abellan van Kan, S Gillette-Guyonnet, S Andrieu, J-F Dartigues, J Touchon, T Dantoine, O Rouaud, M Bonnefoy, P Robert, M-N Cuffi, L Bories, S Bordes, Y Gasnier, F Desclaux, K Sudres, A Pesce, B Vellas.   

Abstract

1680 participants were randomized over the recruitment period in MAPT study. A total of 1290 participants were recruited in the 7 University Hospital centers, and 390 participants in the 6 memory clinics around Toulouse Gerontopole / Alzheimer Disease research clinical center. The first randomization was on May 30, 2008, and the targeted number of randomized participants was reached on February 24, 2011; 2595 subjects were finally screened, of which 1680 fulfilled the eligibility criteria which represents 64.8%. Approximately, one quarter of screened people refused to participate after the detailed presentation of the study and 4.3% were still interested in participating but missed for unknown reasons the baseline visit even after repeated contacts. Of the 1810 subjects who signed the consent for participating to the study at the baseline visit, 130 (7.1%) were excluded because one of the eligibility criteria was not satisfied. Interestingly, the higher percentage of randomizations compared to screened participants is the personal contact source; almost 85 % of screened participants entered in the study. In an equivalent way, Medias and conferences are efficient recruiting sources to enrol volunteers in the study. Unexpectedly, only about 60% of screened participants from the hospital and GP sources were randomized and 33.2% from health care services. Almost a quarter of the randomized participants come from the hospital outpatients clinics and approximately 20% from public conferences. A total of 1128 contacts yielded to 556 screened volunteers and 345 randomized participants in the coordinating center of Toulouse. Thus, 30 % of contacts were recruited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499458     DOI: 10.1007/s12603-012-0046-8

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  7 in total

1.  Primary care practitioners on the front line of Alzheimer's disease care.

Authors:  Stephane Oustric; Marie Eve Rouge-Bugat; Bruno Vellas
Journal:  J Am Med Dir Assoc       Date:  2011-10       Impact factor: 4.669

2.  IAGG workshop: health promotion program on prevention of late onset dementia.

Authors:  S Andrieu; I Aboderin; J P Baeyens; J Beard; A Benetos; G Berrut; M Brainin; H B Cha; L K Chen; P Du; B Forette; F Forette; A Franco; L Fratiglioni; S Gillette-Guyonnet; G Gold; F Gomez; R Guimaraes; D Gustafson; A Khachaturian; J Luchsinger; F Mangialasche; H Mathiex-Fortunet; J P Michel; E Richard; L S Schneider; A Solomon; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 3.  Improving recruitment of older people to research through good practice.

Authors:  Marion E T McMurdo; Helen Roberts; Stuart Parker; Nikki Wyatt; Helen May; Claire Goodman; Stephen Jackson; John Gladman; Sinead O'Mahony; Khalid Ali; Edward Dickinson; Paul Edison; Chris Dyer
Journal:  Age Ageing       Date:  2011-09-11       Impact factor: 10.668

4.  Recruitment and retention of older adults in aging research.

Authors:  Lona Mody; Douglas K Miller; Joanne M McGloin; Marcie Freeman; Edward R Marcantonio; Jay Magaziner; Stephanie Studenski
Journal:  J Am Geriatr Soc       Date:  2008-12       Impact factor: 5.562

5.  Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease.

Authors:  Sophie Gillette-Guyonnet; Sandrine Andrieu; Thierry Dantoine; Jean-François Dartigues; Jacques Touchon; B Vellas
Journal:  Alzheimers Dement       Date:  2009-03       Impact factor: 21.566

Review 6.  How to get older people included in clinical studies.

Authors:  Miles D Witham; Marion E T McMurdo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  A road map for the recruitment and retention of older adult participants for longitudinal studies.

Authors:  Janet Bonk
Journal:  J Am Geriatr Soc       Date:  2010-10       Impact factor: 5.562

  7 in total
  26 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

2.  Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.

Authors:  P Payoux; J Delrieu; A Gallini; D Adel; A S Salabert; A Hitzel; C Cantet; M Tafani; D De Verbizier; J Darcourt; Ph Fernandez; J Monteil; I Carrié; T Voisin; S Gillette-Guyonnet; M Pontecorvo; B Vellas; S Andrieu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-08       Impact factor: 9.236

3.  Advances in the prevention of Alzheimer's disease and dementia.

Authors:  A Solomon; F Mangialasche; E Richard; S Andrieu; D A Bennett; M Breteler; L Fratiglioni; B Hooshmand; A S Khachaturian; L S Schneider; I Skoog; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

Review 4.  Facilitating Alzheimer disease research recruitment.

Authors:  Joshua D Grill; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

5.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06

Review 6.  Amyloid imaging in Alzheimer's disease: a literature review.

Authors:  P Saidlitz; T Voisin; B Vellas; P Payoux; A Gabelle; M Formaglio; J Delrieu
Journal:  J Nutr Health Aging       Date:  2014-07       Impact factor: 4.075

7.  The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease.

Authors:  Sarah D Tarrant; Shoshana H Bardach; Kendra Bates; Heather Nichols; Jacqueline Towner; Clay Tamatha; Allison Caban-Holt; Linda J Van-Eldik; Richard R Murphy; Reisa Sperling; Gregory A Jicha
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

Review 8.  Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential.

Authors:  Md Tanvir Kabir; Md Sahab Uddin; Philippe Jeandet; Talha Bin Emran; Saikat Mitra; Ghadeer M Albadrani; Amany A Sayed; Mohamed M Abdel-Daim; Jesus Simal-Gandara
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

9.  Recruiting Persons with Dementia and Caregivers in a Clinical Trial: Dyads Perceptions.

Authors:  Miranda V McPhillips; Darina V Petrovsky; Glenna S Brewster; Junxin Li; Nalaka S Gooneratne; Nancy A Hodgson; Justine S Sefcik
Journal:  West J Nurs Res       Date:  2021-04-17       Impact factor: 1.774

10.  Prevention strategies for Alzheimer's disease.

Authors:  Serge Gauthier; Liyong Wu; Pedro Rosa-Neto; Jianping Jia
Journal:  Transl Neurodegener       Date:  2012-06-28       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.